The jab manufactured by a drug producing company known as Pfizer is currently under clinical trials.
Efforts to completely oust the Covid-19 pandemic are multiplying with a recent move being the manufacture of another vaccine by a world leading drug company, Pfizer, said to be able to prevent the deadly coronavirus. Pfizer is reported to have already manufactured 'several hundred thousand doses' of the jab at its plant in Puurs, Belgium. The vaccine has been hoarded for clinical trails and will only be distributed worldwide if the trials are a success, and regulators deem it safe and effective, sources have confirmed. Reports further indicate that the US giant hopes to make 100 million doses available this year, of which 40 million are destined for the UK. If the vaccine is confirmed, sources say, every patient who receives the vaccine will need two doses. Talking with an international media outlet, yesterday, Pfizer UK boss Ben Osborn says: “It was great to see the first vial coming off the manufacturing line.” “It just brought a tremendous smile to my face to see all of this work actually result in a product,” he adds.
This recent development comes to add to several other proposals which on several occasions sparked controversies. On August 11, 2020, Russia became the first country in the world to approve a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine, which is based on two adenovirus vectors, was developed by the Gamaleya National Center of Epidemiology and Microbiology (Moscow, Russia). Its approval was announced by President Vladimir Putin. After some time, the vaccine sparked a lot of controversies and it was sent to the back door. According to WHO, as of August 28, 2020, nine vaccine candidates were in late-stage trials. These included separate adenovirus vector vaccines, a couple of mRNA vaccines, and several inactivated virus vaccines. The UN body states that the availability of a safe and effective vaccine for Covid-19 is well-recognized as an additional tool to contribute to the control of the pandemic. At the same time, the organisation cautions that the challenges and efforts needed to rapidly develop, evaluate and produce this at scale are enormous. “It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable,” WHO underlines. That is why to be sure of what is distributed as Covid-19 vaccine, WHO insists that, “we must test all candidate vaccines until they fail”. Hopes are high that this recent development from Pfizer will pass the litmus test.
- 24 nov. 2020 13:57
- 0 likes
- 24 nov. 2020 13:10
- 0 likes
- 24 nov. 2020 13:03
- 0 likes